Products for Research Use Only

EPZ020411

CAT: 0804-HY-12970-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12970-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
EPZ020411 is a selective inhibitor of PRMT6 with an IC50 of 10 nM, has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 can be used for the research of cancer[1][2].
CAS Number
1700663-41-7
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Histone Methyltransferase
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/EPZ020411.html
Purity
98.07
Solubility
DMSO : 4.76 mg/mL (ultrasonic; adjust pH to 7 with 1 M HCl)
Smiles
CNCCN(C)CC1=CNN=C1C2=CC=C(O[C@H]3C[C@H](OCCC4CCOCC4)C3)C=C2
Molecular Formula
C25H38N4O3
Molecular Weight
442.59
Precautions
H302, H315, H319, H335
References & Citations
[1]Mitchell LH, et al. Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 ToolCompound. ACS Med Chem Lett. 2015 Apr 6;6 (6) :655-659.|[2]He Y, et al. Inhibition of Protein arginine methyltransferase 6 reduces reactive oxygen species production and attenuates aminoglycoside- and cisplatin-induced hair cell death. Theranostics. 2020 Jan 1;10 (1) :133-150.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PRMT1; PRMT6; PRMT8
Citation 01
Acta Pharmacol Sin. 2022 Feb;43 (2) :457-469.|Bioorg Chem. 2024 May 10:148:107439.|Brain. 2024 Jul 5;147 (7) :2552-2565.|Cell Death Dis. 2023 Oct 9;14 (10) :655.|EMBO Rep. 2018 Dec;19 (12) :e46377.|Exp Cell Res. 2022 Nov 16;422 (1) :113413.|J Transl Med. 2024 Oct 10;22 (1) :922.|J Transl Med. 2025 Jan 16;23 (1) :74.|J Immunother Cancer. 2025 Mar 13;13 (3) :e010639.